

DUKE UNIVERSITY MEDICAL CENTER

CURRICULUM VITAE

Date Prepared: December 2018

(Use "NA" for no entry and use continuation pages when necessary)

Name (complete with degrees): Paolo Mannelli MD

Primary academic appointment: Associate Professor, Psychiatry and Behavioral Sciences

Primary academic department (not DUAP): Psychiatry and Behavioral Sciences

Secondary appointment (if any) - (department): NA

Present academic rank and title (if any): Associate Professor, Psychiatry and Behavioral Sciences,
Track V, Duke University, Durham, NC 27705

Date and rank of first Duke Faculty appointment: September 2004, Clinical Associate Professor

Medical Licensure: North Carolina License # 00791

Date of License (Month/Day/Year): 08/12/2004

Specialty certification(s) and dates (Month/Day/Year): General Psychiatry 07/11/1990 (Italy)

Date of birth 03/01/1959 Place (include city/state/country): Grosseto/Italy

Citizen of Italy

Visa status (if applicable): Permanent Resident, United States of America

Education	<u>Institution</u>	<u>Date</u>	(Year)	<u>Degree</u>
High School	Liceo Classico "Carducci", Grosseto, Italy	1978		Maturita'
College	NA			
Graduate or Professional School	Universita' Cattolica S Cuore, Roma, Italy A. Gemelli Medical School	1986		M.D

Professional training and academic career (chronologically, beginning with first postgraduate position):

<u>Institution</u>	<u>Position/Title</u>	<u>Dates</u>
A. Gemelli Medical School and University Hospital	Resident in Psychiatry	1986-1990
Clinica S. Alessandro, Roma, Italia	Staff Physician	1986-1990
Universita' Cattolica' del Sacro Cuore Department of Psychiatry	Voluntary Assistant	1986-1990
University of California S. Francisco Langley Porter Psychiatric Institute	Visiting Research Scientist	1989-1990
Universita' Cattolica' del Sacro Cuore Department of Psychiatry A. Gemelli University Hospital, Roma	University Medical Doctor in Charge of Assistance (MIUCA) Attending Psychiatrist Consultant in Drug Dependence	1990-1997 1990- 2000
Universita' Cattolica del Sacro Cuore	Assistant Professor of Psychiatry with tenure	1997- 2003
A. Gemelli University Hospital, Roma	Level I Medical Director Department of Psychiatry	1998- 2003
Thomas Jefferson Univ., Philadelphia Dept Psychiatry and Human Behavior	Visiting Research Scientist	2000- 2001
Thomas Jefferson Univ., Philadelphia Dept Psychiatry and Human Behavior	Adj Research Assistant Professor	2001- 2003
Thomas Jefferson Univ., Philadelphia Dept Psychiatry and Human Behavior	Research Associate Professor	2003- 2004
Duke University, Durham Dept Psychiatry and Behav Sciences	Clinical Associate Professor	2004- 2006
Duke University, Durham Dept Psychiatry and Behav Sciences	Associate Professor	2006-continue
Duke University Medical Center	Active Medical Staff	2005-continue
Duke University Medical Center	Associate Medical Director Duke Addictions Program	2006-continue
Duke Regional Hospital	Active Medical Staff	2007-2013
Duke University Medical Center	Medical Director Center for Addiction Science And Technology	2017-continue

Publications

1. Refereed journals: (Refereed journals are scientific publications that have active editorial boards and a system of critical review of all submissions for publication)
- I. Named author
 1. Tempesta E., Janiri L., Pirrongelli C., **Mannelli P.** Lefetamina: aspetti di un farmaco d'abuso. *Bollettino per le Farmacodipendenze e l'Alcolismo*, 6, 721-745, 1984.
 2. Janiri L., **Mannelli P.**, Agnes M., Ciaramella A. La valutazione dell'abuso di nuove sostanze attraverso una scala per la rilevazione degli effetti psicotropi dei farmaci: Considerazioni metodologiche. *Rassegna di Igiene Mentale VIII*, 1, 191-194, 1986.
 3. Janiri L., **Mannelli P.**, Conte G.L., Di Giannantonio M., Tempesta E. New abused substances and related dependence syndromes: Clinical evaluation and methodological approach. *Acta Medica Romana Universitatis Catholicae Sacri Cordis*, 25(1), 113- 125, 1987.
 4. Janiri L., **Mannelli P.** Validita' conoscitiva e interpretazione di modelli sperimentali in alcuni disturbi psichiatrici. *Rivista di Neuropsichiatria e Scienze Affini*, XXIII-3, 179-207, Luglio-Settembre 1987.
 5. Tempesta E., **Mannelli P.**, Janiri L. Il "confine" etico in psicofarmacologia. *Medicina e Morale*, 5, 817-835, 1987.
 6. **Mannelli P.**, Janiri L., Tempesta E. Proposta e verifica di una "rating scale" per la valutazione degli effetti di farmaci psicotropi, in relazione al potenziale di abuso. *Formazione Psichiatrica*, 4, 303-332, 1987.
 7. Janiri L., **Mannelli P.**, Pirrongelli C., Lo Monaco M., Tempesta E. Lephphetamine abuse and dependence: clinical effects and withdrawal syndrome. *British Journal of Addiction*, 84, 89-95, 1989.
 8. Presutti E., **Mannelli P.**, Troncon R. L'alcolismo al confine tra psicosi e creativita': un caso clinico. *Alcolologia*, 1(3), 227-233, 1989.
 9. **Mannelli P.**, Janiri L., De Marinis M., Tempesta E. Lephphetamine: new abuse of an old drug- Clinical evaluation of opioid activity. *Drug and Alcohol Dependence*, 24, 95-101, 1989.
 10. Tempesta E., Janiri L., **Mannelli P.**, Persico A.M., Diodato S. Clinical reports on recent abuse of an antitussive. *British Journal of Addiction*, 85, 815-816, 1990.
 11. Janiri L., Tempesta E., **Mannelli P.**, Persico A.M., Diodato S. Zipeprol is a new antitussive with an opiate spectrum and hallucinogenic effects. *Drug and Alcohol Dependence*, 27(2), 121-125, 1991.
 12. **Mannelli P.**, Mazza S., Janiri L., Tempesta E. Ipotesi serotoninergiche sui meccanismi d'azione della cocaina. *Bollettino di Psichiatria Biologica*, 7(3), 56-59, 1991.

13. De Marinis M., Magnifico F., Janiri L., **Mannelli P.**, Taranto C., Pulito M.L. Headache in cocaine abusers. *Cocaine Today: Its Effects on the Individual and Society, Biological and Clinical Aspects of Cocaine Use*. United Nations Interregional Crime and Justice Research Department (UNICRI), pp. 103-105, 1991.
14. Janiri L., Di Giovanni A., Persico A.M., Zeppetelli E., **Mannelli P.**, Antico L., Tempesta E. Consumo di benzodiazepine e rischio di dipendenza in pazienti geriatrici istituzionalizzati. *Minerva Psichiatrica*, 32, 151-163, 1991.
15. **Mannelli P.**, Jones R.T. The use of buprenorphine in the treatment of cocaine abuse: Preliminary results of a study on drug interactions in man. *Cocaine Today: Its Effects on the Individual and Society, Biological and Clinical Aspects of Cocaine Use*. United Nations Interregional Crime and Justice Research Department (UNICRI), pp. 358-362, 1991.
16. Tempesta E., Janiri L., **Mannelli P.** Patterns of cocaine abuse and indications for treatment. *European Neuropsychopharmacology*, 1(3): 259-261, 1991.
17. Janiri L., Gobbi G., Serretti A., Zeppetelli E., Di Matteo N., **Mannelli P.** Fattori predittivi in alcolisti trattati con anticomulsivi. *Archivio di Psichiatria Generale*, 2 Suppl: 247-250, 1992.
18. Serretti A., **Mannelli P.**, Janiri L., Pulito M.L. Caratterizzazione della sintomatologia astinenziale in corso di trattamento differenziato per la disintossicazione da oppiacei. *Archivio di Psichiatria Generale*, 2: 123-127, 1992.
19. Pulito M.L., **Mannelli P.**, Janiri L., Tempesta E. Abuso di alcol e polifarmacodipendenza. *Archivio di Psichiatria Generale*, 2:11-13, 1992.
20. Janiri L., Troncon R., **Mannelli P.**, Zeppetelli E., Hadjichristos A., Tempesta E. Individuazione di sottogruppi all'interno di una popolazione di alcolodipendenti divezzati, sulla base del mantenimento dello stato "alcohol-free." *Archivio di Psichiatria Generale*, 1: 1-9, 1992.
21. **Mannelli P.**, Mizzoni M.C., Janiri L., Tempesta E. Influenza sul tono dell'umore di differenti trattamenti farmacologici per la disintossicazione da oppiacei: Esperienze cliniche con clonidina e ketorolac. *Archivio di Psichiatria Generale*, 2 S:119-122, 1992.
22. **Mannelli P.**, Janiri L., Tempesta E., Jones R. T. Prediction in drug abuse: cocaine interactions with alcohol and buprenorphine. *British Journal of Psychiatry*, 163/S21, pp. 39-45, Sept. 1993.
23. **Mannelli P.**, Di Giannantonio M., Mizzoni M.C., Andreani R., Janiri L., Pozzi G., Tempesta E. Farmacodipendenza, sieropositività ed AIDS: Analisi di un campione ambulatoriale di pazienti tossicodipendenti. *Archivio di Psichiatria Generale*, 3: 225-228, 1993.
24. Guidi L., Bartoloni C., Di Giovanni A., Antico L., Corsi F., Pili R., Triccerri A., Janiri L., **Mannelli P.**, Pariante C., Menini E., Carbonin P., Gambassi G. Psychological status, life and social conditions: A study in a population of institutionalized elderly people. *International Journal of Geriatric Psychiatry*, 8: 419-426, 1993.
25. Janiri L., **Mannelli P.**, Serretti A., Tempesta E. Low-dose buprenorphine detoxification in long-term methadone addicts. *Regulatory Peptides*, 1, 289-290, Feb. 1994.

26. Janiri L., **Mannelli P.**, Persico A. M., Serretti A., Tempesta E. Opiate detoxification of methadone maintenance patients using lefetamine, clonidine, and buprenorphine. *Drug and Alcohol Dependence*, 36: 139-145, 1994.
27. **Mannelli P.**, Janiri L., Mizzoni M. C., Tempesta E. Sources of differentiation of cocaine withdrawal symptomatology. *European Neuropsychopharmacology*, 4 (3): 401-402, 1994.
28. Gobbi G., Hadjichristos A., Zeppetelli E., **Mannelli P.**, Janiri L. Effetti della fluoxetina sulla compulsivita' alcol-orientata: studio in doppio cieco versus placebo. *Archivio di Psichiatria Generale*, 1: 137-139, 1994.
29. Tempesta E., Janiri L., and **Mannelli P.** GABAergic drugs and addictive behavior. *European Neuropsychopharmacology*, 5 (3): 217-218, 1995.
30. Janiri L., **Mannelli P.**, Pozzi G., Conte G.L. Aspetti clinici del craving: modelli concettuali e dimensioni psicopatologiche. *Psichiatria e Psicoterapia Analitica*, XIV,1: 79-96, 1995.
31. Hadjichristos A., Janiri L., Rago R., **Mannelli P.**, Tempesta E. Trazodone as a possible anticomulsive drug in alcoholism: a preliminary study in the post-detoxification period. *European Neuropsychopharmacology*, 5 (3): 399-400, 1995.
32. Janiri L., **Mannelli P.**, Gobbi G., Serretti A., Pozzi G., Tempesta E. Effects of fluoxetine at antidepressant doses on short-term outcome of detoxified alcoholics. *International Clinical Psychopharmacology*, 11: 109-117, 1996
33. **Mannelli P.**, Mizzoni M.C., Janiri L., Lombardi U., De Risio S., Tempesta E. Craving for alcohol and dopamine activity. *Biological Psychiatry*. 1997; 42:35-38
34. Janiri L, Hadjichristos A, Buonanno A, Rago R, **Mannelli P.**, de Risio S. Adjuvant trazodone in the treatment of alcoholism: an open study. *Alcohol and Alcoholism*, Jul-Aug; 33(4):362-365, 1998.
35. De Giacomo M, Gaspari R, Stefanelli A, Barelli A, **Mannelli P.** Emergency therapeutical approach simulating ultrarapid opioid detoxification in methadone withdrawal precipitated by erroneous administration of naltrexone. *European Journal of Emergency Medicine*, Jun; 6(2):153-155, 1999.
36. Pozzi G, Del Borgo C, Del Forno A, Genuardo A, **Mannelli P.**, Fantoni M. Psychological discomfort and mental illness in patients with AIDS: implications for home care. *Aids Patient Care STDS*. Sep;13(9):555-564, 1999.
37. **Mannelli P.**, De Risio S, Pozzi G, Janiri L, De Giacomo M. Serendipitous rapid detoxification from opiates: the importance of time-dependent processes. *Addiction*. 94(4):589-591, Apr1999.
38. Tempesta E., **Mannelli P.**, Pozzi G. Stress-related changes in Drug Abuse Behavior. *Current Opinion in Psychiatry*. 1999; 12, 1 (vol. 1): 135-36.
39. **Mannelli P.**, Gottheil E, Buonanno A, De Risio S. Use of very low-dose naltrexone during opiate detoxification. *Journal of Addictive Disease*. 22(2):63-69, 2003.

40. Thornton C, Patkar A, Murray H, **Mannelli P**, Gottheil E, Vergare M, Weinstein S. High- and Low-Structure Treatments for Substance Dependence: Role of Learned Helplessness. *The American Journal of Drug and Alcohol Abuse*, 29(3); 567-584, 2003.
41. Murray H, Patkar A, **Mannelli P**, De Maria P, Desai A, Vergare M. Relationship between aggression, sensation-seeking, and impulsivity with severity of cocaine use. *Addictive Disorders and Their Treatment*, 2(4):113-121, December 2003.
42. Patkar A, Thornton C, **Mannelli P.**, Hill K, Gottheil E, Vergare M, Weinstein S. Comparison of pretreatment characteristics and treatment outcomes for alcohol, cocaine and multisubstance-dependent patients. *Journal of Addictive Disease*, 23 (1): 93-109, 2004.
43. Patkar A, Berrettini W H, **Mannelli P**, Gopalakrishnan R, Hoehe M, Certa K, Bilal L, Gottheil E. Relationship between Serotonin transporter gene polymorphisms and platelet serotonin transporter sites among African-American cocaine dependent individuals and healthy volunteers. *Psychiatric Genetics*, 14(1):25-32, March 2004.
44. Patkar A, Murray E, **Mannelli P**, Gopalakrishnan R, Weinstein S, Vergare M. Pre-treatment measures of impulsivity, aggression and sensation-seeking are associated with treatment outcome for African-American cocaine dependent individuals. *Journal of Addictive Disease*, 23(2):109-122, 2004.
45. **Mannelli P**, Gottheil E, Peoples J, Oropeza V, Van Bockstaele EJ. Chronic very low naltrexone administration attenuates opioid withdrawal expression. *Biological Psychiatry*, 56(4):261-8, 2004.
46. Patkar AA, **Mannelli,P**, Peindl K, Murray H, Vergare MJ, Berrettini WH. Relationship of serum prolactin with severity of drug use and treatment-outcome in Cocaine Dependence. *Psychopharmacology*. 176(1):74-81, Oct 2004
47. McCarthy LE, **Mannelli P**, Niculescu M, Gingrich K, Unterwald EM, Ehrlich ME. The distribution of cocaine in mice differs by age and strain. *Neurotoxicology and Teratology*, 26(6):839-848, Nov-Dec 2004.
48. Smith RG, Han AM, Crowley JJ, Doyle GA, Oslin DW, Patkar AA, **Mannelli P**, DeMaria, PA, O'Brien CP, & Berrettini WH. Novel exonic mu opioid receptor gene (OPRM1) polymorphisms not associated with opioid dependence. *American Journal of Medical Genetics*, 5;133(1):105-109, Feb 2005
49. Patkar A, Batra V, **Mannelli P**, Evers-Casey S, Vergare M, Leone F. Medical symptoms associated with tobacco smoking with and without marijuana use among crack cocaine dependent patients. *The American Journal on Addictions*, 14:43-53, 2005
50. **Mannelli P**, Patkar AA, Murray HW, Certa K, Peindl K, Mattila-Evenden M, Berrettini WH. Polymorphism in the serotonin transporter gene and response to treatment in African-American cocaine and alcohol abusing individuals. *Addiction Biology*, 10(3):261-268, 2005
51. Ray R, Doyle GA, Crowley JJ, Buono RJ, Oslin DW, Patkar AA, **Mannelli P**, Demaria PA Jr, O'brien CP, Berrettini WH. A functional prodynorphin promoter polymorphism and opioid dependence. *Psychiatric Genetics*. 2005 Dec;15(4):295-298.

52. Patkar AA, **Mannelli P**, Peindl K, Hill KP, Gopalakrishnan R, Berrettini WH. Relationship of disinhibition and aggression to blunted prolactin response to meta-Chlorophenylpiperazine in cocaine dependent patients. *Psychopharmacology (Berl)*. 2006 Jan 17;;1-10.
53. Van Bockstaele E.J., Rudoy C, **Mannelli P**, Oropeza V, Qian Y. Elevated μ opioid receptor expression in the nucleus of the solitary tract accompanies attenuated withdrawal signs following chronic low naltrexone in opiate dependent rats. *Journal of Neuroscience Research* 2006 Feb 15;83(3):508-514.
54. Patkar AA, **Mannelli P**, Peindl K, Murray HW, Maier B, Leone FT. Changes in tobacco smoking following treatment for cocaine dependence. *The American Journal of Drug and Alcohol Abuse* 2006, 32(2):135-148.
55. Patkar, AA., Peindl, K, Mago R, **Mannelli, P**, Masand, PS. An Open-Label, Rater-Blinded, Augmentation Study of Aripiprazole in Treatment-Resistant Depression. *Primary Care Companion to the Journal of Clinical Psychiatry*, 2006;8(2):82-87.
56. **Mannelli P**, Gottheil E, Van Bockstaele E. Antagonist treatment of opioid withdrawal: Translational low dose approach. *Journal of Addictive Disease*, 2006;25(2):1-8.
57. Patkar, AA., Peindl, K, Mago R, **Mannelli, P**, Masand, PS. An Open-Label, Rater-Blinded, Augmentation Study of Aripiprazole in Treatment-Resistant Depression. *Primary Care Companion to the Journal of Clinical Psychiatry*, 2006;8(2):82-87.
58. Patkar AA, **Mannelli P**, Hill KP, Peindl K, Pae CU, Lee TH. Relationship of prolactin response to meta-chlorophenylpiperazine with severity of drug use in cocaine dependence. *Human Psychopharmacology*. 2006 Aug;21(6):367-75.
59. **Mannelli P**, Patkar AA, Peindl K, Tharwani H, Gopalakrishnan R, Hill KP, Berrettini WH. Polymorphism in the serotonin transporter gene and moderators of prolactin response to meta-chlorophenylpiperazine in African-American cocaine abusers and controls. *Psychiatry Research*. 2006 Nov 15;144(2-3):99-108. Epub 2006 Sep 25.
60. Patkar AA, Masand PS, Pae CU, Peindl K, Hooper-Wood C, **Mannelli P**, Ciccone P. A randomized, double-blind, placebo-controlled trial of augmentation with an extended release formulation of methylphenidate in outpatients with treatment-resistant depression. *Journal of Clinical Psychopharmacology*. 2006 Dec;26(6):653-6.
61. Patkar AA, Masand PS, Krulewicz S, **Mannelli P**, Peindl K, Beebe KL, Jiang W. A randomized, controlled, trial of controlled release paroxetine in fibromyalgia. *American Journal of Medicine*. 2007 May;120(5):448-54.
62. Davidson C, Gopalan R, Ahn C, Chen Q, **Mannelli P**, Patkar AA, Weese GD, Lee TH, Ellinwood EH. Reduction in methamphetamine induced sensitization and reinstatement after combined pergolide plus ondansetron treatment during withdrawal. *European Journal of Pharmacology*. 2007 Jun 22;565(1-3):113-8. Epub 2007 Mar 12.
63. **Mannelli P**, Pae CU. Medical comorbidity and alcohol dependence. *Current Psychiatry Reports*. 2007 Jun;9(3):217-24.

64. Tharwani HM, Yerramsetty P, **Mannelli P**, Patkar A, Masand P. Recent advances in poststroke depression. *Current Psychiatry Reports*. 2007 Jun;9(3):225-31.
65. Peindl KS, **Mannelli P**, Wu LT, Patkar AA. Trends in nonheroin opioid abuse admissions: 1992-2004. *Journal of Opioid Management*. 2007 Jul-Aug;3(4):215-23.
66. **Mannelli P**, Patkar AA, Peindl K, Murray HW, Wu LT, Hubbard R. Effectiveness of low-dose naltrexone in the post-detoxification treatment of opioid dependence. *Journal of Clinical Psychopharmacology*. 2007 Oct;27(5):468-74.
67. **Mannelli P**, Peindl K, Masand PS, Patkar AA. Long-acting injectable naltrexone for the treatment of alcohol dependence. *Expert Review of Neurotherapeutics*. 2007 Oct;7(10):1265-77.
68. Peindl KS, Masand P, **Mannelli P**, Narasimhan M, Patkar A. Polypharmacy in pregnant women with major psychiatric illness: a pilot study. *Journal of Psychiatric Practice*. 2007 Nov;13(6):385-92.
69. Pae CU, Masand PS, Peindl K, **Mannelli P**, Han C, Marks DM, Patkar AA. An open-label, rater-blinded, flexible-dose, 8-week trial of escitalopram in patients with major depressive disorder with atypical features. *Primary Care Companion to the Journal of Clinical Psychiatry*. 2008;10(3):205-10.
70. Patkar AA, **Mannelli P**, Peindl K, Hill KP, Wu LT, Lee T, Kuhn C. Relationship of the serotonin transporter with prolactin response to meta-chlorophenylpiperazine in cocaine dependence. *Journal of Psychiatric Research*. 2008 Oct;42(14):1213-9.
71. Wu LT, Ringwalt CL, **Mannelli P**, Patkar AA. Prescription pain reliever abuse and dependence among adolescents: a nationally representative study. *Journal of the American Academy Child Adolescent Psychiatry*. 2008 Sep;47(9):1020-9.
72. Wu LT, Ringwalt CL, **Mannelli P**, Patkar AA. Hallucinogen use disorders among adult users of MDMA and other hallucinogens. *American Journal of Addiction*. 2008 Sep-Oct;17(5):354-63.
73. Han C, Masand PS, Krulewicz S, Peindl K, **Mannelli P**, Varia IM, Pae CU, Patkar AA. Childhood abuse and treatment response in patients with irritable bowel syndrome: a post-hoc analysis of a 12-week, randomized, double-blind, placebo-controlled trial of paroxetine controlled release. *J Clinical Pharmacology Therapeutics*. 2009 Feb;34(1):79-88.
74. Masand PS, Pae CU, Krulewicz S, Peindl K, **Mannelli P**, Varia IM, Patkar AA. A double-blind, randomized, placebo-controlled trial of paroxetine controlled-release in irritable bowel syndrome. *Psychosomatics*. 2009 Jan-Feb;50(1):78-86.
75. **Mannelli P**, Patkar AA, Peindl K, Gorelick DA, Wu LT, Gottheil E. Very low dose naltrexone addition in opioid detoxification: a randomized, controlled trial. *Addiction Biology*. 2009 Apr;14(2):204-13.
76. **Mannelli P**, Patkar AA, Peindl K, Gottheil E, Wu LT, Gorelick DA. Early outcomes following low dose naltrexone enhancement of opioid detoxification. *American Journal on Addictions*. 2009 Mar-Apr;18(2):109-16.

77. Wu LT, Parrott AC, Ringwalt CL, Patkar AA, **Mannelli P**, Blazer DG. The high prevalence of substance use disorders among recent MDMA users compared with other drug users: Implications for intervention. *Addictive Behaviors*. 2009 Aug;34(8):654-61.
78. Pae CU, Masand PS, Marks DM, Krulewicz S, Han C, Peindl K, **Mannelli P**, Patkar AA. History of early abuse as a predictor of treatment response in patients with fibromyalgia: A post-hoc analysis of a 12-week, randomized, double-blind, placebo-controlled trial of paroxetine controlled release. *World Journal of Biological Psychiatry*. 2009 Apr 20:1-7.
79. Pae CU, Masand PS, Marks DM, Krulewicz S, Peindl K, **Mannelli P**, Patkar AA. History of depressive and/or anxiety disorders as a predictor of treatment response: a post hoc analysis of a 12-week, randomized, double-blind, placebo-controlled trial of paroxetine controlled release in patients with fibromyalgia. *Progress in Neuropsychopharmacology and Biological Psychiatry*. 2009 Aug 31;33(6):996-1002.
80. Pae CU, Marks DM, Masand PS, Peindl K, Hooper-Wood C, Han C, **Mannelli P**, Ciccone P, Patkar AA. Methylphenidate extended release (OROS MPH) for the treatment of antidepressant-related sexual dysfunction in patients with treatment-resistant depression: results from a 4-week, double-blind, placebo-controlled trial. *Clinical Neuropharmacology*. 2009 Mar-Apr;32(2):85-8.
81. Patkar AA, Rozen S, **Mannelli P**, Matson W, Pae CU, Krishnan KR, Kaddurah-Daouk R. Alterations in tryptophan and purine metabolism in cocaine addiction: a metabolomic study. *Psychopharmacology (Berl)*. 2009 Oct;206(3):479-89.
82. **Mannelli P**, Patkar A, Rozen S, Matson W, Krishnan R, Kaddurah-Daouk R. Opioid use affects antioxidant activity and purine metabolism: preliminary results. *Human Psychopharmacology*. 2009 Dec;24(8):666-75.
83. **Mannelli P**, Peindl K, Patkar AA, Wu LT, Pae CU, Gorelick DA. Reduced cannabis use after low-dose naltrexone addition to opioid detoxification. *J Clin Psychopharmacol*. 2010 Aug;30(4):476-8.
84. **Mannelli P**. Agonist-antagonist combinations in opioid dependence: a translational approach. *Dipendenze Patologiche*, 2010, 1:17-24.
85. **Mannelli P**, Peindl K, Patkar AA, Wu LT, Tharwani HM, Gorelick DA. Problem drinking and low-dose naltrexone-assisted opioid detoxification. *J Stud Alcohol Drugs*. 2011 May;72(3):507-13.
86. Wu LT, Woody GE, Yang C, **Mannelli P**, Blazer DG. Differences in onset and abuse/dependence episodes between prescription opioids and heroin: results from the National Epidemiologic Survey on Alcohol and Related Conditions. *Subst Abuse Rehabil*. 2011 May;2011(2):77-88.
87. **Mannelli P**, Peindl KS, Wu LT. Pharmacological enhancement of naltrexone treatment for opioid dependence: a review. *Subst Abuse Rehabil*. 2011 Jun;2011(2):113-123.
88. **Mannelli P**. Once-monthly extended-release naltrexone injections improve opioid abstinence over 24 weeks compared with placebo *Evid Based Ment Health*, Nov 2011; 14(4):106.

89. Proeschold-Bell RJ, Patkar AA, Naggie S, Coward L, **Mannelli P**, Yao J, Bixby P, Muir AJ. An integrated alcohol abuse and medical treatment model for patients with hepatitis c. *Dig Dis Sci*. 2012 Apr;57(4):1083-91.
90. **Mannelli P**, Peindl K, Wu LT, Patkar AA, Gorelick DA. The combination very low-dose naltrexone-clonidine in the management of opioid withdrawal. *Am J Drug Alcohol Abuse*. 2012 May;38(3):200-5.
91. **Mannelli P**, Peindl KS, Lee TH, Bhatia KS, Wu LT. Buprenorphine-mediated transition from opioid agonist to antagonist treatment: state of the art and new perspectives. *Curr Drug Abuse Rev*. 2012 Mar 1;5(1):52-63.
92. Lee TH, Szabo ST, Fowler JC, **Mannelli P**, Mangum OB, Beyer WF, Patkar AA, Wetsel WC. Pharmacologically-mediated reactivation and reconsolidation blockade of the psychostimulant-abuse circuit: A novel treatment strategy. *Drug Alcohol Depend*. 2012 Jul 1;124(1-2):11-8.
93. Wu LT, Swartz MS, Wu Z, **Mannelli P**, Yang C, Blazer DG. Alcohol and drug use disorders among adults in emergency department settings in the United States. *Ann Emerg Med*. 2012 Aug;60(2):172-80.
94. Wu LT, Swartz MS, Pan JJ, Burchett B, **Mannelli P**, Yang C, Blazer DG. Evaluating brief screeners to discriminate between drug use disorders in a sample of treatment-seeking adults. *Gen Hosp Psychiatry*. 2013 Jan-Feb;35(1):74-82.
95. **Mannelli P**. The burden of caring: drug users & their families. *Indian J Med Res*. 2013 Jul;137(4):636-8.
96. **Mannelli P**, Wu LT, Peindl KS, Gorelick DA. Smoking and opioid detoxification: behavioral changes and response to treatment. *Nicotine Tob Res*. 2013 Oct;15(10):1705-13.
97. Wu LT, Blazer DG, Gersing KR, Burchett B, Swartz MS, **Mannelli P**; NIDA AAPI Workgroup. Comorbid substance use disorders with other Axis I and II mental disorders among treatment-seeking Asian Americans, Native Hawaiians/Pacific Islanders, and mixed-race people. *J Psychiatr Res*. 2013 Dec;47(12):1940-8.
98. Wu LT, Brady KT, **Mannelli P**, Killeen TK; NIDA AAPI Workgroup. Cannabis use disorders are comparatively prevalent among nonwhite racial/ethnic groups and adolescents: a national study. *J Psychiatr Res*. 2014 Mar;50:26-35.
99. **Mannelli P**, Wu LT, Peindl KS, Swartz MS, Woody GE. Extended release naltrexone injection is performed in the majority of opioid dependent patients receiving outpatient induction: a very low dose naltrexone and buprenorphine open label trial. *Drug Alcohol Depend*. 2014 May 1;138:83-8.
100. Proeschold-Bell RJ, Reif S, Taylor B, Patkar A, **Mannelli P**, Yao J, Quinlivan EB. Substance use outcomes of an integrated HIV-substance use treatment model implemented by social workers and HIV medical providers. *Health and Social Work*, 2015 DOI: 10.1093/hsw/hlv088
101. **Mannelli P**, Wu LT. Family substance use screening: less to hide, more to gain. *Indian J Med Res*. 2016 Jun;143 (6):682-684.

102. **Mannelli P**, Wu LT. Primary care for opioid use disorder. *Subst Abuse Rehabil.* 2016 Aug 16; 7:107-9.
103. Wu LT, Zhu H, **Mannelli P**, Swartz MS. Prevalence and correlates of treatment utilization among adults with cannabis use disorder in the United States. *Drug Alcohol Depend.* 2017 Aug 1;177:153-162.
104. Wu LT, Ghitza UE, Burns AL, **Mannelli P**. The opioid overdose epidemic: opportunities for pharmacists. *Subst Abuse Rehabil.* 2017 Jul 31;8:53-55.
105. LT Wu LT, Ghitza UE, Zhu H, Spratt S, Swartz M, **Mannelli P**. Substance use disorders and medical comorbidities among high-need, high-risk patients with diabetes *Drug and Alcohol Dep*, 2018 Mar 3;186:86-93
106. Bisaga A, **Mannelli P**, Sullivan M, Vosburg S, Compton P, Woody G, Kosten T. The Role of Antagonists in the Medical Management of Opioid Use Disorders: A Review of Historical and Existing Treatment Strategies. *American Journal on Addictions*, 2018 Apr; 27(3):177-187.
107. Bisaga A, **Mannelli P**, Yu M, Nangia N, Graham CE, Tompkins DA, Kosten TR, Akerman SC, Silverman BL, Sullivan MA. Outpatient transition to extended-release injectable naltrexone for patients with opioid use disorder: a phase 3 randomized trial. *Drug and Alcohol Dependence*, 2018 Jun 1;187:171-178.
108. John WS, He Zhu H, **Mannelli P**, Schwartz RP, Subramaniam GA, Wu LT. Prevalence, patterns, and correlates of multiple substance use disorders among adult primary care patients *Drug and Alcohol Dependence*, 2018 Jun 1;187:79-87.
109. Proeschold-Bell RJ, Evon DM, Makarushka C, Wong JB, Datta SK, Yao J, Patkar AA, **Mannelli P**, Hodge T, Naggie S, Wilder JM, Fried MW, Niedzwiecki D, Muir AJ. The Hepatitis C-Alcohol Reduction Treatment (Hep ART) intervention: Study protocol of a multi-center randomized controlled trial. *Contemp Clin Trials.* 2018 Sep;72:73-85.
110. **Mannelli P**, Swartz M, Wu LT. Withdrawal severity and early response to treatment in the outpatient transition from opioid use to extended release naltrexone. *Am J Addict.* 2018 Sep;27(6):471-476.
111. John WS, Zhu H, **Mannelli P**, Subramaniam GA, Schwartz RP, McNeely J, Wu LT. Prevalence and patterns of opioid misuse and opioid use disorder among primary care patients who use tobacco. *Drug Alcohol Depend.* 2018 Nov 26;194:468-475.

II. Study Group publications (Multicenter trials that you were PI but not author)

III. Letters

IV. Editorials

Pubmed IDs of Published Work in My Bibliography:

<http://www.ncbi.nlm.nih.gov/myncbi/paolo.mannelli.1/bibliography/47227942/public/?sort=date&direction=ascending>

2. Books: (Indicate authors or editor.)

3. Chapters in books:

1. Janiri L., **Mannelli P.**, Tempesta E. La valutazione degli effetti centrali e del potenziale tossicomane di farmaci psicotropi mediante "rating scales." In: Sarteschi P., Maggini C., Guazzelli M. (Eds.) La Ricerca Psicofarmacologica: Stato Attuale e Prospettive. ETS, Pisa, Vol. I, 307- 313, 1989.
2. Janiri L., **Mannelli P.**, Pozzi G., Di Giannantonio M. Depressione e ansia nei comportamenti d'abuso e nella dipendenza da sostanze. In: Spinetti, G. (Ed.), Depressione e Ansia: Aspetti eziologici, sociali, clinici e terapeutici in una società che cambia. Centro Studi Psichiatria e Territorio, 71-87, 1992.
3. Di Giannantonio M., **Mannelli P.**, Pozzi G., Tempesta E. Psichiatria e sindromi HIV-correlate: Dall'emergenza alla prevenzione del disturbo mentale. In: Vella G, Siracusano A (Eds.) Emozioni e Psichiatria, U.T.E.T., Milano, 243-262, 1996.
4. Tempesta E., **Mannelli P.** Interferenze delle sostanze d'abuso sulla fertilità umana. In: Garcea N., Dargenio R., Isidori A. (Eds.) Progressi clinici: Ginecologia e ostetricia, Vol 3, 3, Ambiente e fertilità, Piccin, Padova, 103-110, 1997.
5. Conte G.L., Di Giannantonio M., Janiri L., **Mannelli P.**, Pozzi G. Il progetto comunitario tra harm-reduction e prospettive di cambiamento. In: Ferro F.M., Di Giannantonio M., Trotta S. (Eds.) Tra deserti e labirinti. Metis Editrice, Chieti, 108-119, 1997.
6. Tempesta E., **Mannelli P.** Effetti psichici di cocaina ed ecstasy. In Gatti R.C (Ed.) Ecstasy e nuove droghe. FrancoAngeli Editore, Milano, 142-148, 1998.
7. **Mannelli P.**, Farina B., Gobbi G., Janiri L. Neurotrasmettitori e Psicomatica. In: Orlandelli E., Satta M.A., Azzoni A. (Eds.) Patologie e Psicologia Medica. Società Editrice Universo, Roma, 61-77, 1998.
8. Tempesta E., **Mannelli P.** Le farmacodipendenze: aspetti diagnostici e terapeutici. (Cap CLXII). In Giusti G (Ed.) Trattato di Medicina Legale e Scienze Affini, vol IV. CEDAM, 1239-1306, 1999.
9. **Mannelli P.** Abuso di cocaina. Farmacoterapia e prevenzione delle ricadute. In: Di Giannantonio M., Ferro F.M., Pierdomenico F. (Eds.) Oltre il Pregiudizio: modelli, idee e strumenti nella prevenzione delle dipendenze. Franco Angeli Editore, Milano, 123-28, 1999.
10. **Mannelli P.**, Wu LT, Brady KT, Age-specific treatment interventions and outcomes: Pharmacological and Integrated treatments in older adults with substance use disorders. In "Substance Misuse and Older Adults" I Crome, P Crome, K Rao, LT Wu Editors, Wiley, Oxford 2014

4. Selected abstracts (from over 300)

1. Janiri L., Pirrongelli C., **Mannelli P.**, Conte G.L. A new rating scale for assessing the effects of psychoactive drugs: focus on addiction. "Psychiatric Rehabilitation," Regional Symposium of World Psychiatric Association, Rome, October 9-13, 1984.
2. Tempesta E., Janiri L., Pirrongelli C., **Mannelli P.** Abuso di lefetamina e valutazione della dipendenza da nuove sostanze psicotrope. Convegno su: Recenti progressi in terapia neuropsicofarmacologica, Sorrento, 23-26 Maggio 1984.
3. Janiri L., **Mannelli P.**, Di Giannantonio M. Fattori psicosociali legati all'incremento dell'abuso di nuovi farmaci. Com:"Igiene Mentale e Ospedale Generale," Congresso in Roma, 21-23 Febbraio, 1986.
4. Janiri L., **Mannelli P.**, Tempesta E. Abuse of lephetamine: a clinical study. Poster: International Narcotics Research Conference, Adelaide, Australia, August 31-September 4, 1987.

5. Tempesta E., Di Giovanni A., Janiri L., **Mannelli P.**, Persico A.M., Antico L. Benzodiazepine use and dependency risk in geriatric patients. Poster: XVIth Collegium Internationale Neuro-Psychopharmacologicum Congress, Munich, Germany, August 15-19, 1988, Abstract in Psychopharmacology, 96: S307, 1988.
6. **Mannelli P.**, Janiri L., Mizzoni C., Casarella N., Favazzo R., Conte G.L., Tempesta E. La buprenorfina nella pratica clinica di disintossicazione da sostanze oppiacee: Caratteristiche del trattamento della sintomatologia astinenziale. Com.: XXXVIII Congresso Nazionale della Societa' Italiana di Psichiatria, Salsomaggiore Terme, 20-26 Ottobre, 1991.
7. Janiri L., Zeppetelli E., Di Matteo N., Gobbi G., **Mannelli P.** A new rating scale for assessment of alcohol withdrawal syndrome (AWRS). Com.: Vth World Congress of Biological Psychiatry. Florence, June 9-14, 1991, Abstract in Biological Psychiatry, 29: 284S, 1991.
8. **Mannelli P.**, Janiri L., Conte G.L., Pozzi G., Tempesta E. Naltrexone maintenance regimen after detoxification with buprenorphine or methadone in opioid addicted patients: Evaluation of the clinical outcome. Poster: Vth World Congress of Biological Psychiatry, Florence, June 9-14, 1991, Abstract in Biological Psychiatry, 29: 495S, 1991.
9. **Mannelli P.**, Janiri L., Casarella N., Di Matteo N., Tempesta E. Opioid detoxification using low doses of buprenorphine: Comparison between the sublingual and intramuscular routes. Poster: Vth World Congress of Biological Psychiatry, Florence, June 9-14, 1991, Abstract in Biological Psychiatry, 29: 504S, 1991.
10. Conte G.L., De Persis F., Favazzo R., **Mannelli P.**, Pozzi G., Zangari M., Tempesta E. Predicting the retention of naltrexone-maintained opiate addicts in two different settings. Poster: XVIII Collegium Internationale Neuropsychopharmacologicum: Prediction in Psychopharmacology, Prague, June 24-27, 1992.
11. Janiri L., **Mannelli P.**, Casarella N., Zeppetelli E., Gobbi G., Pulito M.L., Tempesta E. Outcome prediction of alcoholics treated with anti-compulsive drugs. Relaz.: XVIII Collegium Internationale Neuropsychopharmacologicum: Prediction in Psychopharmacology, Prague, June 24-27, 1992.
12. **Mannelli P.**, Janiri L., Tempesta E. Prediction in drug abuse: cocaine interactions with alcohol and buprenorphine. Relaz.: XVIII Collegium Internationale Neuropsychopharmacologicum: Prediction in Psychopharmacology, Prague, June 24-27, 1992.
13. **Mannelli P.**, Di Giannantonio M., Mizzoni M.C., Andreani R., Janiri L., Pozzi G., Tempesta E. Farmacodipendenza, sieropositivita' ed AIDS: Analisi di un campione ambulatoriale di pazienti tossicodipendenti. Com.: I Congresso Nazionale S.I.C.A.D., Roma 7-10 Ottobre 1992.
14. **Mannelli P.**, Mizzoni M.C., Janiri L., Tempesta E. Influenza sul tono dell'umore di differenti trattamenti farmacologici per la disintossicazione da oppiacei: Esperienze cliniche con clonidina e ketorolac. Com.: I Congresso Nazionale S.I.C.A.D., Roma 7-10 Ottobre 1992.
15. **Mannelli P.**, Serretti A., Janiri L. Caratterizzazione della sintomatologia astinenziale in corso di trattamento differenziato per la disintossicazione da oppiacei. Com.: I Congresso Nazionale S.I.C.A.D., Roma 7-10 Ottobre 1992.
16. De Gaetano A., **Mannelli P.**, Mizzoni M.C., Castagneto M. Modello matematico di analisi del disagio psicofisico in corso di disintossicazione da sostanze d'abuso. Poster: I Congresso Nazionale S.I.C.A.D., Roma 7-10 Ottobre 1992.
17. Pulito M.L., **Mannelli P.**, Janiri L., Tempesta E. Abuso di alcol e polifarmacodipendenza. Com.: I Congresso Nazionale S.I.C.A.D., Roma 7-10 Ottobre 1992.

18. Janiri L., Gobbi G., Serretti A., Zeppetelli E., **Mannelli P.** Fattori predittivi in alcolisti trattati con anticompulsivi. Com.: I Congresso Nazionale S.I.C.A.D., Roma 7-10 Ottobre 1992.
19. Di Giannantonio M., **Mannelli P.**, Mizzoni M. C., Pozzi G., Tempesta E. Methadone therapy, psychiatric disturbances, and compliance to treatment in IVDUs, HIV+ outpatients. Poster: IXth International Conference on AIDS, Berlin, June 7-11, 1993.
20. **Mannelli P.**, Mizzoni M.C., Janiri L., Tempesta E. Cocaine abstinence symptoms and craving treatment. Com.: IXth World Congress of Psychiatry, Rio de Janeiro, 6-12 Giugno 1993, abstract 1300, p. 331, 1993.
21. Janiri L., Pulito M.L., **Mannelli P.**, Tempesta E. Poly-addiction among alcoholics in a Drug Dependence Unit population. Com.: 9th World Congress of Psychiatry, Rio de Janeiro, 6-12 Giugno 1993, abstract 1393, p. 354, 1993.
22. Tempesta E., **Mannelli P.**, Janiri L. Problemi metodologici e prospettive nella valutazione del craving per sostanze d'abuso Relaz.: XXXIX^o Congresso Nazionale della Societa' Italiana di Psichiatria, Riccione 23-28 Ottobre 1994.
23. Tempesta E., Janiri L., Bignamini A.A., and **Mannelli P.** The efficacy and safety of acamprosate on the maintenance of abstinence in weaned alcoholics. Com: 57th CPDD Scientific Meeting, Scottsdale, Arizona, June 10-15, 1995.
24. Janiri L., **Mannelli P.** Abuso di stimolanti e comorbilita Psichiatrica. Relaz.: X^o Congresso della Societa Italiana di Neuropsicofarmacologia, Venezia 27-29 Settembre 1995.
25. Tempesta E., **Mannelli P.**, Mizzoni M.C. Gli indicatori biologici. Relaz.: XIV^o Congresso Nazionale Societa Italiana di Alcolologia, Castel S. Pietro Terme (Bo) 10-12 Ottobre 1996.
26. Tempesta E., **Mannelli P.**, Janiri L., Mizzoni M.C. Dopamine regulation and addictive behavior in alcoholics and opiate addicts. Com: 58th CPDD Scientific Meeting, S. Juan Portorico, June 22-27, 1996.
27. Tempesta E., **Mannelli P.** European experience with narcotic antagonists in the treatment of opioids and alcohol dependence. Relaz: XXth Collegium Internationale Neuro-Psychopharmacologicum Congress, Melbourne, Australia, June 23-27, 1996, Abstract in European Neuropsychopharmacology,(6), S3, p 163, 1996.
28. Tempesta E., Janiri L., and **Mannelli P.** Alcohol dependence and depression: Nosographic and therapeutic approaches. Relaz: Xth World Congress of Psychiatry, Madrid, August 23-28, 1996.
29. Janiri L., **Mannelli P.**, Pozzi G., Hadjichristos A., De Risio S. Differentiation of craving and compulsivity in detoxified alcoholics. Poster: Xth World Congress of Psychiatry, Madrid, August 23-28, 1996.
30. Janiri L., **Mannelli P.**, Hadjichristos A. Unicità o difformità delle sindromi astinenziali. Relaz: XL^o Congresso Nazionale della Societa' Italiana di Psichiatria, Palermo, 18-24 Ottobre 1997.
31. **Mannelli P.**, Mizzoni M.C., Niutta M.G., Baldelli C., Amato L., Tempesta E. Sistema dopaminergico e 'craving' per l'eroina: Implicazioni terapeutiche. Com: XL^o Congresso Nazionale della Societa' Italiana di Psichiatria, Palermo, 18-24 Ottobre 1997.

32. Di Giannantonio M., Pozzi G., **Mannelli P.**, Genuardo A., Fantoni M., Del Borgo C. Psychological problems and psychopharmacological intervention in the home care of AIDS patients. Relaz: World Psychiatric Association Regional Meeting, Rome, June 16- 19, 1997.
33. Di Giannantonio M., Tonioni F., **Mannelli P.** Ethics and the treatment of drug-dependent patients. Relaz: World Psychiatric Association Regional Meeting, Rome, June 16- 19, 1997.
34. Sarchiapone M., Janiri L., **Mannelli P.**, Hadjichristos A., Fiorentini A. Clinical features response to placebo in dysthymic patients. Relaz: World Psychiatric Association Regional Meeting, Rome, June 16- 19, 1997.
35. Persico B., Sabatino A., Janiri L., **Mannelli P.** "Unexpected" effects of psychopharmacological drugs on addicts' behavior. Com: World Psychiatric Association Regional Meeting, Rome, June 16- 19, 1997.
36. Janiri L., Calvosa F., Caroppo E., Hadjichristos A., Buonanno A., Rago R., Farina B., **Mannelli P.** Assessing craving in alcoholism with a composite instrument. Com: World Psychiatric Association Regional Meeting, Rome, June 16- 19, 1997.
37. Janiri L., Hadjichristos A., Lombardi U., Rago R., **Mannelli P.**, Tempesta E. SSRIs in alcoholism: fluvoxamine Vs fluoxetine in alcoholic outpatients. *Biological Psychiatry*. 1997; 42:35S
38. **Mannelli P.**, Buonanno A., De Risio S. The use of antagonists in treating opiate withdrawal. *European Neuropsychopharmacology*. 1999; 9, S5: S345
39. Janiri L., Pozzi G., **Mannelli P.**, Frustaci A. Influenza degli eventi traumatici e stressanti sul decorso dei disturbi da uso di sostanze *Giornale Italiano di Psicopatologia*. 2000; 6,S1:42
40. Buonanno A, Pozzi G, **Mannelli P**, Bertagnolio S, De Risio S. Trattamento dei sintomi psicotici in pazienti con patologie HIV-correlate: confronto tra neurolettici tradizionali e risperidone. XLII Congresso Nazionale della Società Italiana di Psichiatria. Torino 16-21 Ottobre 2000. Abstract Book, pg 789.
41. **Mannelli P.**, Gottheil E, Vogel W, Van Bockstaele E.. Very low dose Naltrexone pretreatment attenuates opiate withdrawal in rats. American Psychiatric Association Meeting, New research abstracts, p185, New Orleans, LA, May-5-10, 2001
42. **Mannelli P.**, Gottheil E, Vogel W, Oropeza V, Peoples J, Van Bockstaele E. Cellular adaptations in brainstem areas by very low naltrexone pretreatment correlate with reduced opiate withdrawal in rats. SFN 31st Annual Meeting, San Diego, CA, Nov 10-15, 2001
43. **Mannelli P.**, Gottheil E, Vogel W, Oropeza V, Peoples J, Van Bockstaele E. Elevated mu opioid receptor expression in the nucleus of the solitary tract accompanies attenuated withdrawal following chronic very low naltrexone in opiate dependent rats. SFN 32nd Annual Meeting, Orlando, FL, Nov 2-7, 2002
44. Buonanno A, Bertagnolio S, Pozzi G, **Mannelli P.**, Cauda R, De Risio S. Tollerabilità e sicurezza del risperidone in pazienti con infezione da HIV. Congresso della Società Italiana di Psicopatologia, Roma Italy, Feb 2003
45. Purcell C, Patkar AA, Batra V, **Mannelli P**, Evers-Casey S, Leone FT. Medical symptoms associated with tobacco smoking with and without marijuana abuse among crack cocaine dependent patients. 9th Annual meeting of the Society for Research in Nicotine and Tobacco , New Orleans, Louisiana, February 2003.

46. **Mannelli P.**, Gottheil E, Thornton C, Weinstein S, Levine M, Salazar C. Continuing care versus revolving door following opiate detoxification. ASAM 34th Annual Medical-Scientific Conference, Toronto, Canada, May 1-4, 2003
47. **Mannelli P.**, Thornton C, Weinstein S, Salazar C, Gottheil E. Low-dose naltrexone administration following opiate discontinuation. American Psychiatric Association Annual Conference, San Francisco, CA, May 2003
48. Bilal, L, Patkar AA, Berrettini WH, **Mannelli P**, Vergare MJ. Relationship between serotonin transporter gene polymorphisms and platelet serotonin transporter sites among African-American cocaine dependent individuals and healthy volunteers. American Psychiatric Association Annual Conference, San Francisco, CA, May 2003.
49. Niculescu M., McCarthy L.E., **Mannelli P.**, Unterwald E.M., Ehrlich M.E.. Pharmacokinetics and behavioral effects of psychostimulants in postweanling, periadolescent and adult mice. Adolescent Brain Development: Vulnerabilities and Opportunities. NY September 18-20, 2003.
50. Murray HW., Patkar AA., Peindl K., **Mannelli P.**, Purcell C, Vergare MJ., Leone FT. Tobacco smoking following treatment for cocaine dependence. American Psychiatric Association Annual Conference, New York, NY, May 1-6, 2004.
51. Frey A., Patkar AA., **Mannelli P.**, Vergare MJ., Mattila-Evenden M, Murray HW., Berrettini WH. Relationship of serum prolactin with severity of drug use and treatment outcome in Cocaine Dependence. American Psychiatric Association Annual Conference, New York, NY, May 1-6, 2004.
52. Mattila-Evenden M, Patkar AA., **Mannelli P.**, Peindl K., Murray HW., Bilal L., Berrettini WH. Relationship of serotonin transporter polymorphism to treatment outcome in Cocaine Dependence. American Psychiatric Association Annual Conference, New York, NY, May 1-6, 2004.
53. Mago R, **Mannelli P.**, Berrettini WH., Murray HW., Gottheil E., Vergare M., Thornton C., Patkar A. Mediators of depression as predictor of outcome in Cocaine Dependence. American Psychiatric Association Annual Conference, New York, NY, May 1-6, 2004.
54. **Mannelli P.**, Thornton C., Gottheil E., Levine M., Weinstein S. Six-month outcome of early outpatient treatment after opioid detoxification. American Psychiatric Association Annual Conference, New York, NY, May 1-6, 2004.
55. M. Niculescu; L.E. McCarthy; **P. Mannelli**; M.E.Ehrlich; E.M. Unterwald. Age- and strain-specific pharmacokinetics and behavioral responses to psychostimulants in mice 34th Annual Meeting Society for Neuroscience, San Diego, CA, October 24-27, 2004.
56. Masand, P., Peindl K., Krulewicz S., **Mannelli P.**, Varia I., Patkar A. A Randomized, Controlled Trial of Paroxetine CR in Irritable Bowel Syndrome. American Psychiatric Association Annual Conference, Atlanta, GA, May 2005.
57. Kathleen Peindl, Ashwin Patkar, Stan Krulewicz, Paolo Mannelli, Indira Varia,, Prakash S. Masand. Psychiatric History as a Predictor of Drug Response in Irritable Bowel Syndrome. American Psychiatric Association Annual Conference, Atlanta, GA, May 2005.
58. **Mannelli P**, Thornton C, Weinstein S, Salazar C, Gottheil E. Low-Dose Naltrexone Administration Following Opiate Discontinuation. American Psychiatric Association Annual Conference, Atlanta, GA, May 2005.
59. Lindsay A, Zeiger A, Matthews P, **Mannelli P**, Peindl K, Handelsman L, Patkar A. Differences in Peripheral Mu-Opioid Receptors Among Substance Abusers. American Psychiatric Association Annual Conference, Atlanta, GA, May 2005.
60. Peindl K, Patkar A, Masand P, **Mannelli P**. A randomized, double-blind, placebo-controlled trial of methylphenidate extended release (OROS MPH) in the treatment of antidepressant-related sexual dysfunction. American Psychiatric Association Annual Conference Toronto, ON Canada, May 2006.

61. Patkar AA, **Mannelli P**, Bennett R, Michalek J, Cook H, Perera P, Masand P. A Randomized, Double-Blind, Placebo-Controlled Trial of Sodium Oxybate in Fibromyalgia Syndrome [FMS]. American Psychiatric Association Annual Conference, Toronto, ON, Canada, May 2006
62. Pae C, Peindl K, Masand P, Hooper-Wood C, Ciccone P, **Mannelli P**, Patkar A. Randomized, Double-Blind, Placebo-Controlled Trial of Methylphenidate Extended Release (OROS MPH) in the Treatment of Antidepressant-Related Sexual Dysfunction. New Clinical Drug Evaluation Unit Annual Conference, Boca Raton, Florida, June 2006.
63. Masand P, Peindl K, Hooper-Wood C, Ciccone P, Pae C, **Mannelli P**, Patkar A. A Randomized, Double-Blind, Placebo-Controlled, Flexible-Dose Trial of Augmentation with OROS Methylphenidate in Treatment-Resistant Depression. New Clinical Drug Evaluation Unit Annual Conference, Boca Raton, Florida, June 2006.
64. Ajwani N, Pae C, Masand P, Peindl K, **Mannelli P**, Patkar A. An Open-Label, Rater-Blinded, 6-week Trial of Escitalopram in Major Depression with Atypical Features. American Psychiatric Association Annual Conference, San Diego, CA, May 2007.
65. Pae C, Masand P, Peindl K, Krulewicz S, **Mannelli P**, Patkar A. Sexual Abuse, Symptom Severity and Treatment Response to Paroxetine Controlled Release (CR) in Irritable Bowel Syndrome (IBS). American Psychiatric Association Annual Conference, San Diego, CA, May 2007.
66. Patkar A, Peindl K, Krulewicz S, **Mannelli P**, Pae C, Masand P. Sexual Abuse, Health Status and Treatment Response to Paroxetine Controlled Release (CR) in Fibromyalgia. American Psychiatric Association Annual Conference, San Diego, CA, May 2007.
67. **Mannelli P**, Patkar A, Peindl K, Ajwani N, Preminger S, Sada A, Hubbard R. Very Low-Dose Naltrexone in the Treatment of Opioid Detoxification. American Psychiatric Association Annual Conference, San Diego, CA, May 2007.
68. Pae C, Masand P, Peindl K, Krulewicz S, Han C, **Mannelli P**, Varia I, Patkar AA. Childhood Abuse History as a Predictor of Treatment Response in Patients with Irritable Bowel Syndrome : A Post-hoc Analysis of a 12-week, Randomized, Double-blind, Placebo-Controlled Trial of Paroxetine CR. American Psychiatric Association Annual Conference, San Diego, CA, May 2007.
69. **Mannelli P**, Peindl K, Wu L, Bhatia K, Jadhav S, Patkar A. Early Outcome Following Low Dose Naltrexone Addition to Opioid Detoxification. American Psychiatric Association Annual Conference, Washington, DC, May 2008.
70. Gopalakrishnan R, Peindl K, **Mannelli P**, Beebe K, Patkar A. Trends In Non-Heroin Opioid Abuse Admissions in The U.S. American Psychiatric Association Annual Conference, Washington, DC, May 2008.
71. Narasimhan M, Peindl K, **Mannelli P**, Patkar A, Masand P., M.D. Pregnancy and Psychotropic Medications American Psychiatric Association Annual Conference, Washington, DC, May 2008.
72. **Mannelli P**, Peindl K, Wu L, Patkar A. Cannabis Use Following Low Dose Naltrexone Addition in Opioid Detoxification. American Psychiatric Association Annual Conference, S Francisco, CA, May 2009.
73. **Mannelli P**, Peindl, K, Patkar, A, Tharwani, H, Wu, LT. Alcohol Use and Addition of Low Dose Naltrexone in Opioid Detoxification. American Psychiatric Association Annual Meeting, New Orleans, LA, May 2010.
74. **Mannelli, P**, Peindl, K, Patkar, A, Tharwani, H, Wu, LT. Very low dose naltrexone and clonidine in the management of opioid withdrawal. ASAM's 42nd Annual Medical-Scientific Conference, Washington, DC, April 14-17, 2011.
75. **Mannelli, P**, Peindl, K, Tharwani, H, Wu, LT. Paper Presentation: Nicotine Dependence, Smoking and Opioid Detoxification. ASAM's 43rd Annual Medical-Scientific Conference, Atlanta, GA, April 19-22, 2012.

76. **Mannelli, P**, Peindl, K, Tharwani, H, Wu, LT. Low dose naltrexone/clonidine treatment and tobacco smoking during opiate detoxification. American Psychiatric Association Annual Meeting, Philadelphia, PA, May 2012.
77. **Mannelli, P**, Peindl, K, Wu, LT. Low dose naltrexone-buprenorphine combinations in the outpatient treatment of opioid addiction: Feasibility, safety, and preliminary results. American Psychiatric Association Annual Meeting, San Francisco, May 2013 and Psychiatric Services, Philadelphia, PA, October 2013.
78. **Mannelli, P**, Peindl, K, Wu, LT. Outpatient transition from opioid abuse to XR-NTX injection using low-dose naltrexone/buprenorphine: Patients' outcome. AAAP Annual Conference, Scottsdale, Az, December 2013.
79. **Mannelli, P**, Peindl, K, Wu, LT. Outpatient induction to extended-release naltrexone (XR-NTX) in African American opioid dependent patients. ASAM's 45th Annual Medical-Scientific Conference, April 2014, Orlando, FL.
80. **Mannelli, P**, Peindl, K, Wu, LT. Feasibility of very low dose naltrexone and buprenorphine transition from opioid use to extended release naltrexone. CPDD 76th Annual Scientific Meeting, Puerto Rico, June 2014.
81. **Mannelli, P**, Peindl, K, Wu, LT. Opioid withdrawal severity, drug use, and outpatient induction onto XR-NTX treatment. . American Psychiatric Association Annual Meeting, Toronto, Canada, May 2015
82. **Mannelli, P**, Peindl, K, Wu, LT. Predictors of induction onto extended release naltrexone (XR-NTX) in patients with opioid use disorder. CPDD 76th Annual Scientific Meeting, Phoenix, AZ, June 2015
83. Bisaga A, **Mannelli P**, Yu M, Nangia N, Graham CE, Tompkins DA, Kosten TR, Akerman SC, Silverman BL, Sullivan, ML. Outpatient Transition to XR-Naltrexone in Opioid Use Disorder. 79th Meeting, College on Problems of Drug Dependence, Montreal, Canada, June 2017
84. **Mannelli P**, Tompkins DA, Akerman SC, Yu M, Nangia N, Graham CE, Sullivan, ML, Kosten TR, Bisaga A. Transition to extended-release naltrexone: Heroin versus prescription opioid users. 28th Annual meeting of the American Academy of Addiction Psychiatry, San Diego, CA December 2017
85. Sullivan MA, **Mannelli P**, Yu M, Nangia N, Graham CE, Tompkins DA, Kosten TR, Akerman SC, Silverman BL, Bisaga A. Outpatient Transition to Extended-release Naltrexone in Patients With Opioid-use Disorder AAAP (2017) American Academy of Addiction Psychiatry - 28th Annual Meeting & Symposium Dec 10, 2017
86. **Mannelli P**, Alam D, Nangia N, Sullivan The transition from buprenorphine maintenance to XR-NTX: a randomized double blind study ASAM (2018) American Society of Addiction Medicine - 49th Annual Meeting Apr 13, 2018
87. Comer S, **Mannelli P**, Alam D, Douaihy A, Nangia N, Akerman S, Zavod A, Silverman B, Sullivan M. Efficacy of oral naltrexone with buprenorphine for transitioning from buprenorphine to XR-NTX: A hybrid residential-outpatient randomized control trial CPDD (2018) College on Problems of Drug Dependence - 80th Annual Meeting Jun 13, 2018
88. Tompkins DA, Nunes EV, Bisaga A, Douaihy A, **Mannelli, P**, Yu M, Nangia N, Sullivan MA, Zavod A, Baseline Characteristics Predictive of Successful Transition onto Extended-release Naltrexone CPDD (2018) College on Problems of Drug Dependence - 80th Annual Meeting Jun 13, 2018
89. Speight L, Zavod A, Compton P, **Mannelli P**, Akerman S, Sullivan M, Kosten T, Bisaga A. Transition to Extended-Release Naltrexone (XR-NTX) in Opioid Use Disorder AANP (2018) American Association of Nurse Practitioners - 2018 National Conference Jun 26 2018
90. Douaihy A, **Mannelli P**, Akerman S, Ramos J, Amoroso E, Zavod A, Sullivan M Transition to

5. Non-refereed publications: (Non-refereed publications refer to those which do not routinely use a system of critical review prior to publication; such articles are often solicited by the publisher)
 - i. Print
 1. Tempesta E., Janiri L., Pirrongelli C., **Mannelli P.** Abuso da lefetamina e valutazione della dipendenza da nuove sostanze psicotrope. In: De Maio e Longo (Eds.) *Recenti Progressi in Terapia Neuropsicofarmacologica*, Liviana Press, Padova, 221-224, 1985.
 2. Janiri L., Diodato S., **Mannelli P.**, Persico A.M., Tempesta E. A survey of cases of zipeprol abuse. In: Nappi G., Agnoli A., Fariello R., (Eds.) *Neurotoxicology: Basic and Clinical Research*, CIC Ed. Internazionali, Roma, pp. 187-191, 1987.
 3. Casarella N., Janiri L., **Mannelli P.**, Troncon R., Tempesta E. Tratti di disordine del comportamento alimentare, alcolismo e depressione. In: *Atti del Simposio Internazionale su: Anoressia Bulimia Obesita'- Disturbi del Comportamento Alimentare*, Roma, 201-202, 1988.
 4. Janiri L., Troncon R., Cecchini S., **Mannelli P.**, Tempesta E. La diagnosi psichiatrica nell'alcolismo: rilevanza ai fini del trattamento. In: *Atti del VII Congresso Nazionale della Societa' Italiana di Alcologia*. Martinucci Mediserve, Napoli, 169-175, 1991.
 5. Di Giannantonio M., Favetta S., Pozzi G., **Mannelli P.** Empatia-Apatia: trasformazioni nelle relazioni d'aiuto. Quali rapporti tra burn-out e AIDS? In: Strologo (Ed.) *Atti del Convegno Burn-out e Operatori: Prendersi Cura di Chi Cura*, Ferrari, Bergamo, 151-170, 1992.
 6. **Mannelli P.**, Janiri L., Mizzone M. C., Casarella N., Favazzo R., Conte G. L., Tempesta E. La buprenorfina nella pratica clinica di disintossicazione da sostanze oppiacee: Caratteristiche del trattamento della sintomatologia astinenziale. In: Cazzullo C.L., Giordano P.L. (Eds.), *La salute mentale verso il 2000*, Atti del XXXVIII Congresso Nazionale della Societa Italiana di Psichiatria, LAM.C.O., Palermo, 1992.
 7. Tempesta E., **Mannelli P.** Igiene mentale e nuove patologie emergenti. In: Colucci d'Amato (Ed.) *Il Contributo dell'Igiene Mentale alla Tutela della Salute*. Atti del XIV Congresso della Lega Italiana d'Igiene Mentale. Napoli, 42-43, 1992.
 8. Janiri L., **Mannelli P.**, Tempesta E. Il dualismo dipendenza fisica-psichica nella concettualizzazione dei disturbi da uso di sostanze. In: Sarteschi P., Guazzelli M. (Eds.) *La neuropsicofarmacologia oggi tra la ricerca e la clinica*. ETS, Pisa, 599-606, 1995.
 9. **Mannelli P.**, Mizzone M.C., Janiri L., Di Giannantonio M., Tempesta E. Il craving nell'abuso di stimolanti. In: Rapisarda V., Virzi A., Uccello M. (Eds.) *L'intervento psicoterapico in Psichiatria. Parte I*. Atti del XXXIX Congresso Nazionale della Societa' Italiana di Psichiatria, Formazione Psichiatrica, XVI (2), 193-196, 1996.
 10. Tempesta E., **Mannelli P.**, Janiri L. Problemi metodologici e prospettive nella valutazione del craving per sostanze d'abuso. In: Rapisarda V., Virzi A., Uccello M. (Eds.) *L'intervento psicoterapico in Psichiatria. Parte I*. Atti del XXXIX Congresso Nazionale della Societa' Italiana di Psichiatria, Formazione Psichiatrica, XVI (2), 197-200, 1996.

11. **Mannelli P.** Craving e nuovi stimolanti: il significato di un sintomo. *Giornale Italiano di Psicopatologia*. 1999; 5, 1: 123-24.

ii. Digital

6. Published scientific reviews (for mass distribution)

7. Position, and background papers

1. Substance Abuse and Mental Health Services Administration and National Institute on Alcohol Abuse and Alcoholism, Medication for the Treatment of Alcohol Use Disorder: A Brief Guide. HHS Publication No. (SMA) 15-4907. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2015.

2. Substance Abuse and Mental Health Services Administration. Clinical Use of Extended-Release Injectable Naltrexone in the Treatment of Opioid Use Disorder: A Brief Guide. HHS Publication No. (SMA) 14-4892R. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2015.

3. U.S. Department of Health and Human Services. Substance Abuse and Mental Health Services Administration. Center for Substance Abuse Treatment: Clinical Advances in Non-agonist Therapies. Report, 2016.

8. Non-authored publications: (Faculty member formally acknowledged in the publication for his/her contributions.)

9. Other

Consultant appointments: (Include US government, state, private organizations, etc.)

Consultant, Program and Medication Protocols Development: "Post-Detoxification Interim Treatment enhancement." SAMHSA/Center of Substance Abuse Treatment and the Philadelphia Coordinating Office of Drug and Alcohol Abuse Programs, 2001-2004

Healthcare Advisory Board 2006 - continues

King Pharmaceutical, consultant, October 2010

Epocrates Honors 2010 – continues

Guidepoint Global Advisors 2010 – continues

Pondera Pharmaceuticals Advisory Board, October 2011

Alkermes Inc, Advisory Board, October 2014, April 2017

Scholarly societies (Alpha Omega Alpha, Sigma Xi, Phi Beta Kappa; etc.):

1. Italian Society of Psychiatry, 1990 -continues

2. Italian Society for the Study of Addictive Behaviors and Dependence, 1992-2007

3. European College of Neuropsychopharmacology, 1991 – 1999

4. American Society for Neuroscience, 2000 – 2004

5. American Medical Association, 2002-2005

6. American Academy of Addiction Psychiatry, 2004 - continues

7. American Society for Addiction Medicine 2005-continues
8. Duke Center for AIDS Research 2006-continues
9. Duke Institute for Brain Sciences (DIBS) Addiction Research Group, 2009-continues
10. Society for Clinical and Translational Science (SCTS) 2010-continues
11. College on Problems of Drug Dependence 2014-continue

Professional awards and special recognitions:

Rotary Foundation Scholar Award. Fellowship at the University of California, San Francisco, Langley Porter Psychiatric Institute, Drug Dependence Laboratory of Reese T. Jones, Professor of Psychiatry, 1989 – 1990.

Co-Chairman, XVIIIth Congress of the Collegium Internationale Neuropsychopharmacologicum (CINP), Satellite Symposium, Prague: Platform Presentation, "Prediction in Drug Abuse," 1992.

Secretary, XXXIXth Congress of the Italian Society of Psychiatry, Riccione, Symposium, "Craving and Drug Addiction," 1994.

Expert panelist for "Craving and Abused Substances" task force: European Addiction Research Society. 1994 –1999.

European Union, European Monitoring Centre for Drugs and Drug Addiction, 'Future leaders in drug addiction' residential course, invited participant, Athens, Greece, October 1996.

Chairman, Second National Congress of the Italian Society for the Study of Addictive Behaviors and Dependence, Catania: Training course, "Craving Evaluation and Treatment," 1996.

Scientific Secretariat, World Psychiatric Organization Regional Meeting, Rome, "Psychiatry in the Three Ages of Man." 1997.

Co-Chairman, ASAM 33rd Annual Medical-Scientific Conference, Atlanta, GA. Symposium: "Recent Developments in Opiate Detoxification," 2002.

Invited Member Duke Center for AIDS Research, 2006-continues

Duke PREMIER Partnership for Excellence in Mental Health Interventions, Education & Research, Faculty member 2007-continues.

Listed in the Marquis Who's Who: "Who's Who in America" 2008-continues

'America's Leading Expert' on Substance Withdrawal 2009-continue

Member of the NIH/NIDA Expert Review Meeting: Very low dose naltrexone and opiate dependence July 16, 2009, Rockville, MD

Member of the International Association of Healthcare Professionals (IAHCP) – "The Leading Physicians of the World" 2012-continues

Member of the SAMHSA/NIAAA/NIDA Consensus Panel on New Pharmacotherapies for Alcohol Use Disorders and related comorbidities, July 16-17, 2012, Rockville MD

Member of the SAMHSA/NIAAAA/NIDA Consensus Panel on New Pharmacotherapies for Opioid Use Disorders and related comorbidities, July 17-18, 2012, Rockville MD

Member of the SAMHSA/NIAAAA/NIDA Expert Panel on Clinical Advances in Non-Agonist Therapies, May 11, 2016, Rockville MD

'Best Reviewer', Pharmacoepidemiology and Drug Safety, 2016

"Outstanding reviewer' Drug and Alcohol Dependence, 2016, 2018

Recipient of the Albert Nelson Marquis Lifetime Achievement Award, 2018

Editorial Experience

a. Editorial Boards

Co-Editor-in Chief "Current Drug Development Reviews, previously Current Drug Abuse Reviews" 2018-current

Dipendenze Patologiche-Addictive Behaviors Editorial Board Member 2011-current

International Scholarly Research Network (ISRN) – Addiction Editorial Board Member 2012-2017

b. Ad Hoc scientific review journals

Addiction, Addiction Biology, American Journal on Addictions, American Journal of Drug and Alcohol Abuse, British Journal of Clinical Pharmacology, Clinical Psychopharmacology, Cognitive and Behavioral Practice, Comprehensive Psychiatry, Clinical Medicine Insights: Therapeutics, COCHRANE Library, Current Drug Abuse reviews, Dipendenze Patologiche-Addictive Behaviors, Drug and Alcohol Dependence, Expert Opinion on Pharmacotherapy, Indian Journal of Medical Research, ISRN Addiction, Journal of Clinical Psychopharmacology, Journal of Experimental Pharmacology, Journal of Psychopharmacology, Journal of Substance Abuse, The Lancet, Metabolic Brain Disease, Neurochemistry International, Neuropsychiatric Disease and Treatment, Neuropsychiatry, Pain Management, Pharmacoepidemiology and Drug Safety, Pharmacology, Biochemistry and Behavior, Pharmacogenomics and Personalized Medicine, Postgrad Medicine, Primary Psychiatry, Substance Abuse, Substance Abuse and Rehabilitation, Substance Abuse: Research and Treatment, Substance Abuse Treatment- Prevention and Policy, Therapeutics and Clinical Risk Management.

Organizations and participation: (Offices held, committee assignments, etc.)

Scientific Review Committees

Health Research Board (HRB) Ireland Health Agency Awards

Swiss National Science Foundation-Swiss National Research Council

External support - gifts, grants, and contracts:

<u>PI</u>	<u>% Effort</u>	<u>Purpose</u>	<u>Approximate Amount</u>	<u>Duration</u>
-----------	-----------------	----------------	---------------------------	-----------------

Past:
(selected)

Mannelli	25	<i>Open label, flexible dose very low dose naltrexone-buprenorphine transfer to XR-NTX naltrexone in opioid dependence</i>	\$400,000	07/12-03/15
Mannelli	25	<i>Place of low-dose Naltrexone in Opiate Detoxification</i>	\$250,000	09/03-07/06
Mannelli	3	<i>VICTORY Registry of XR-NTX treatment</i>	\$20,000	08/11-07/13
Wu	5	<i>Epidemiology of Nonmedical Prescription Analgesic Use</i>	\$600,000	04/07-07/12
Proeschold-Bell	5	<i>Carolina Alcohol and Drug Expansion Team (CADET)</i>	\$900,000	09/07-09/12
Wu	5	<i>Classification of Substance Use Severity and Treatment Outcomes: NIDA CTN Studies</i>	\$500,000	09/09-08/13
Wu	5	<i>Southern Consortium Node of Clinical Trials Network Screening, Brief Intervention, and Referral to Treatment in Primary Care</i>	\$400,000	01/13-08/16
Mannelli	6	<i>Retrospective Evaluation of Zubsolv Outcomes-A Longitudinal View (RESOLV)</i>	\$20,000	11/15-12/16
Reif	6	<i>Carolina Alcohol and Drug Resources (CADRE) Targeted Capacity Expansion Program for Substance abuse Treatment for Ethnic Minority Populations at High risk for HIV/AIDS</i>	\$700,000	09/12-08/17
Wu	6	<i>Substance abuse & treatment gaps in Asians, Pacific Islanders & multiple-race Individuals</i>	\$400,000	07/13-01/18
Muir	6	<i>Integrated care research for patients with chronic liver disease</i>	\$800,000	09/13-05/18
McClernon	12	<i>Use of low-tobacco content cigarettes for smoking cessation</i>	\$400,000	01/15-12/18
Present:				
Wu	10	<i>NIDA CTN Mid-Southern (Primary Care Networks) Node</i>	\$800,000	11/15-10/20
Mannelli	30	<i>A Phase 3 Study to Evaluate the Safety, Tolerability, and Efficacy of Naltrexone for use in Conjunction with Buprenorphine in Adults with Opioid Use Disorder Prior to First Dose of VIVITROL</i>	\$400,000	01/16-08/18
Robertson	5	<i>A feasibility study for testing the effects of extended-release naltrexone on recidivism and other participant outcomes in drug court settings</i>	\$339,000	10/16-12/18
Mannelli	30	<i>A Phase 3 Study to Evaluate the Safety,</i>	\$400,000	02/17-12/19

*Tolerability, and Efficacy of Naltrexone for use
in Conjunction with Buprenorphine in Adults
with Opioid Use Disorder Transitioning from
Buprenorphine Maintenance
Prior to First Dose of VIVITROL®*

Wu-Mannelli	25	<i>Physician-Pharmacist Collaboration in the Management of Patients with Opioid Use Disorder-CTN-Concept study</i>	\$900,000	06/17-12/19
-------------	----	--	-----------	-------------

Pending:

Mannelli		Extended-Release Naltrexone Treatment of Emergency Department Patients with Opioid Use Disorder (NTX-ED-OD)	\$330,000	04/19-03/21
----------	--	---	-----------	-------------

Mentoring activities

- i. Faculty
- ii. Fellows, doctoral, post docs
- iii. Resident
- iv. Medical students

Education / Teaching activities (Residents, Medical students, CME)

- i. Teaching and supporting Learners
 1. Lecturer and Seminar Leader on specific topics in the field of Drug Dependence for medical students in courses of Psychiatry and Psychopharmacology, for residents in Psychiatry, and for non-university psychiatrists and medical doctors. Universita' Cattolica S. Cuore, Roma, Italia. 1990 – 2000
 2. Professor of "Psychology of Deviance" at the L.U.M.S.A. (St. Mary Free University of Social Science), Roma, Italia. 1994 – 1996
 3. Lecturer for medical students, residents in psychiatry and Ph.D. candidates in basic science disciplines. Jefferson Medical College, and Farber Institute of Neuroscience, Philadelphia, PA. 2001-2004
 4. Lecturer in Alcohol and Drug Addiction for PGY 2-3-4 and 5 residents in Psychiatry. Duke University Medical Center 2006-current
- ii. Development of courses/educational programs
- iii. Development of assessment tools and methods
- iv. Education management/ Leadership

Invited Lectures and Presentations

1. Named Lectures
2. Visiting Professorships

3. International Meetings (Selected)

1. **Mannelli P.**, Mizzoni M.C., Tempesta E. Il sistema di gratificazione nella ricerca clinica: Valutazione del craving cocainico. Relaz.: I Congresso Nazionale a partecipazione Internazionale della Societa'

Italiana per lo Studio dei Comportamenti di Abuso e delle Dipendenze (S.I.C.A.D.), Roma 7-10 Ottobre 1992.

2. **Mannelli P.**, Mizzoni M.C., Janiri L., Di Giannantonio M., Tempesta E. Il craving nell'abuso di stimolanti. Relaz.: XXXIX^o Congresso Nazionale della Societa' Italiana di Psichiatria, Riccione 23-28 Ottobre 1994.
3. **Mannelli P.** Gli interventi farmacologici nella dipendenza da cocaina, tra astinenza e ricaduta. Relaz.: Il Congresso Nazionale a partecipazione Internazionale della Societa' Italiana per lo Studio dei Comportamenti di Abuso e delle Dipendenze (S.I.C.A.D.), Acireale(CT), 16-22 Giugno 1996.
4. **Mannelli P.**, Janiri L., Di Giannantonio M. From 'pleasure' to 'craving' in drug addiction. Relaz: World Psychiatric Association Regional Meeting, Rome, Italy, June 16- 19, 1997.
5. **Mannelli P.**, Janiri L., Persico B. Condizionamento e farmacoterapia nella prevenzione delle ricadute. Relaz: XL^o Congresso Nazionale della Societa' Italiana di Psichiatria, Palermo, 18-24 Ottobre 1997.
6. **Mannelli P.**, Biological markers of addictions and pharmacological treatments. XLIV Conference of the Italian Society of Psychiatry, Chieti October 15-20 2006.
7. **Mannelli P.** Outpatient Induction onto XR-NTX Using Naltrexone-Buprenorphine. ISAM Conference, Dundee, UK, October 5-7, 2015.
4. National Scientific Meetings (invited)
1. **Mannelli P.**, Gottheil E. Very low antagonist dosing in opiate detoxification. ASAM 32nd Annual Medical-Scientific Conference, Los Angeles, CA, Apr 19-22, 2001, abs in Journal of Addictive Disease, 20(2) 157, 2001
2. **Mannelli P.**, Gottheil E, Van Bockstaele E, Weinstein S. Using antagonist drugs during opiate administration and withdrawal. ASAM 33rd Annual Medical-Scientific Conference, Atlanta, GA, April 25-28, 2002.
3. **Mannelli P.** Naltrexone regulation of opioid withdrawal. Jefferson University, Department of Psychiatry Meeting, Philadelphia PA, September 8, 2003.
4. **Mannelli P.** Low dose Naltrexone to treat Opioid Dependence. Jefferson University, Department of Psychiatry Meeting, Philadelphia PA, May 25, 2004.
5. **Mannelli P.** The use of Antagonist Drugs in the Treatment of opioid Withdrawal. Farber Institute of Neuroscience scientific meeting, Philadelphia PA, June 25, 2004.
6. **Mannelli P.**, Peindl K, Patkar A, Tharwani H, Ajwani N, Mathew T. Serotonin transporter gene and moderators of prolactin response to meta-Chlorophenylpiperazine in African American cocaine abusers and controls. American Psychiatric Association Annual Conference, Toronto On, Canada, May 2006.
7. **Mannelli P.** Very low dose naltrexone and opiate withdrawal. NIH/NIDA Expert Review Meeting, Bethesda MD, July 16, 2009.
8. **Mannelli, P.** Naltrexone: New Formulations and Indications. Ultra-Low Dose Naltrexone for Drug Addiction. ASAM's 42nd Annual Medical-Scientific Conference, Washington, DC, April 14-17, 2011.
9. **Mannelli P.** Outpatient induction of individuals with OUD onto XR-NTX using very low dose ntx-buprenorphine. Alkermes Inc. Advisory Board Meeting on New Treatments for the outpatient transition from opioid use to XR-NTX therapy, October 6, 2014, New York, NY.

10. **Mannelli P.** Outpatient transition from opioid use to XR-NTX using very low dose naltrexone-buprenorphine, Alkermes Investigator Research Summit on Injectable Extended-Release Naltrexone (XR-NTX), Bethesda MD, March 15, 2015.
11. **Mannelli P.** Individuals with co-occurring disorders: Naltrexone and comorbidities. SAMHSA/NIDA Meeting. Clinical Advances in Non-Agonist Therapies, Rockville MD, May 11 2016.
12. **Mannelli P, Nunes E,** Naltrexone-based treatment of Opioid Use Disorder in the office-based outpatient setting: patient selection and treatment initiation (Workshop). 28th Annual meeting of the American Academy of Addiction Psychiatry, San Diego, CA December 2017.
5. Instructional Courses, workshops, symposiums (National)
6. Posters (National meeting)
7. Regional presentations and posters
1. **Mannelli P,** Very low dose naltrexone and opioid detoxification, Duke University, Translational Addiction Seminars, Durham, August 22, 2005.
2. **Mannelli P,** Naltrexone-assisted detoxification and opioid treatment. Grand Rounds, Duke University Dept of Psychiatry, Durham, NC, November 30, 2006.
3. **Mannelli P,** Naltrexone-assisted detoxification and opioid treatment. Grand Rounds, John Umstead Hospital, Butner NC, November 30, 2006.
4. **Mannelli P,** Opioid agonist antagonist combinations and Clinical effects. King Pharmaceuticals Grand Rounds, Cary NC, October 18, 2010
5. **Mannelli P.** Expert discussant: Addiction Psychiatry, 'Problem drinking and low-dose naltrexone-assisted opioid detoxification' Department of Psychiatry Chair's Rounds Duke University Medical Center, December 3, 2012.
6. **Mannelli P.** Medications for substance abuse and individuals with HIV: Updates and reminders. Carolinas Alcohol and Drug Resources (CADRE) annual meeting. Durham, September 25, 2013.
7. **Mannelli P.** The Treatment of Opioid Use Disorders. Clinical Connections, Jewish Family Services, Durham, September 21, 2018

Clinical activity - type of practice and estimate of time commitment:

Outpatient Psychiatric Clinic, drug addiction and comorbid disorders, office based buprenorphine and naltrexone treatment, about 15%-20% effort

Participation in academic and administrative activities of the University and Medical Center

- i. Administrative activities
PI grant management, Research staff supervision, Duke Addictions Program/Duke Psychiatry Specialty Clinic Cary: General/Employee supervision
- ii. Committees
SBR Advisory Board, Department of Psychiatry. Duke University Medical Center, 2012-2014
Affiliations: Addiction Division; Division of Social & Community Psychiatry

Grand Rounds Psychiatry, DIBS/CABC seminars

iii. Leadership positions

Medical Director, Center for Addiction Science and Technology, Duke University Medical Center

Associate Medical Director, Duke Addictions Program, Duke University Medical Center